{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:50:39Z","timestamp":1793130639574,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>A causal role of type-I interferons (IFN-I) in autoinflammatory type-I interferonopathies such as SAVI (STING\u2013associated vasculopathy with onset in infancy) and CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures) is suggested by elevated expression of IFN-I stimulated genes (ISGs). Hitherto, the lack of specific inhibitors of IFN-I signaling has prevented the verification of a causal role for IFN-I in these conditions. Commonly used inhibitors of the JAK\/STAT pathway exert broad effects on multiple signaling pathways leading to more general immunosuppression beyond IFN-I signaling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here we show in four patients with SAVI and one patient with CANDLE syndrome that blockade of the IFNAR1 receptor (Anifrolumab) exerts an additive effect over JAK-inhibitor alone. In two patients with SAVI, monotherapy with Anifrolumab is sufficient to retain a suppressed IFN-I signature and clinical improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Anifrolumab normalizes IFN-I signature genes and relieves symptoms beyond what is typically achieved by a JAK-inhibitor (Baricitinib) alone in patients with type-I interferonopathies. In two patients Anifrolumab was used successfully as monotherapy. Addition of Anifrolumab enabled steroid tapering and cessation with reduced overall immunosuppression and lower risks of opportunistic infections and improved metabolic states and growth which is highly beneficial in these young\u00a0patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results verify a causal role of IFN-I signaling in type-I Interferonopathies SAVI and CANDLE and suggests Anifrolumab as an important new treatment option in autoinflammatory diseases with elevated IFN-I induced gene expression.<\/jats:p>\n                    <jats:p>Genia Kretzschmar, Laura Pi\u00f1ero P\u00e1ez, and Ziyang Tan are shared-first authors.<\/jats:p>\n                    <jats:p>Sara Alehashemi, AnnaCarin Horne, and Petter Brodin are co-senior author.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10875-024-01826-2","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T01:02:49Z","timestamp":1729645369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies"],"prefix":"10.1007","volume":"45","author":[{"given":"Genia","family":"Kretzschmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Pi\u00f1ero","family":"P\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin Habimana","family":"Mugabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarom\u00edr","family":"Mike\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadepally","family":"Lakshmikanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaela","family":"Goldbach-Mansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Palmblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alehashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnnaCarin","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Brodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"1","key":"1826_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","volume":"1238","author":"YJ Crow","year":"2011","unstructured":"Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N York Acad Sci. 2011;1238(1):91\u20138.","journal-title":"Ann N York Acad Sci"},{"issue":"3","key":"1826_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/jmg.40.3.183","volume":"40","author":"YJ Crow","year":"2003","unstructured":"Crow YJ, Black DN, Ali M, et al. Cree encephalitis is allelic with Aicardi-Gouti\u00e9res syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism. J M\u00e9d Genet. 2003;40(3):183.","journal-title":"J M\u00e9d Genet"},{"key":"1826_CR3","doi-asserted-by":"crossref","unstructured":"Yin L, Jesus AA, Bernadette M, et al. Activated STING in a Vascular and Pulmonary Syndrome. N Engl J Med. 2014;371(6):507\u201318.","DOI":"10.1056\/NEJMoa1312625"},{"issue":"6","key":"1826_CR4","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ajhg.2010.10.031","volume":"87","author":"AK Agarwal","year":"2010","unstructured":"Agarwal AK, Xing C, DeMartino GN, et al. PSMB8 Encoding the \u03b25i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet. 2010;87(6):866\u201372.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"1826_CR5","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1172\/JCI81260","volume":"125","author":"A Brehm","year":"2015","unstructured":"Brehm A, Liu Y, Sheikh A, et al. Additive loss-of-function proteasome subunit mutations in CANDLE\/PRAAS patients promote type I IFN production. J Clin Investig. 2015;125(11):4196\u2013211.","journal-title":"J Clin Investig"},{"issue":"1","key":"1826_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41435-018-0029-9","volume":"20","author":"S Patel","year":"2019","unstructured":"Patel S, Jin L. TMEM173 variants and potential importance to human biology and disease. Genes Immun. 2019;20(1):82\u20139.","journal-title":"Genes Immun"},{"issue":"49","key":"1826_CR7","doi-asserted-by":"publisher","first-page":"eabb1662","DOI":"10.1126\/sciimmunol.abb1662","volume":"5","author":"LD Notarangelo","year":"2020","unstructured":"Notarangelo LD, Bacchetta R, Casanova JL, Su HC. Human inborn errors of immunity: An expanding universe. Sci Immunol. 2020;5(49):eabb1662.","journal-title":"Sci Immunol"},{"issue":"7","key":"1826_CR8","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GAM Sanchez","year":"2018","unstructured":"Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Investig. 2018;128(7):3041\u201352.","journal-title":"J Clin Investig"},{"issue":"1","key":"1826_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/1744666X.2023.2268284","volume":"20","author":"N Gensous","year":"2024","unstructured":"Gensous N, Lazaro E, Blanco P, Richez C. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus. Expert Rev Clin Immunol. 2024;20(1):21\u201330.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"1826_CR10","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jaip.2024.02.013","volume":"12","author":"M-A Doroudchi","year":"2024","unstructured":"Doroudchi M-A, Thauland TJ, Patel BA, Butte MJ. Anifrolumab to treat a monogenic interferonopathy. J Allergy Clin Immunol: Pr. 2024;12(5):1374-1376.e1.","journal-title":"J Allergy Clin Immunol: Pr"},{"key":"1826_CR11","unstructured":"Alehashemi S, Baumgardner A, Shakoory B, et al. Anifrolumab normalizes the type I interferon signature in a cohort of patients with type I interferonopathies [Internet]. Arthritis and Rheumatology; 2023. p. 1.Available from: https:\/\/acrabstracts.org\/abstract\/anifrolumab-normalizes-the-type-i-interferon-signature-in-a-cohort-of-patients-with-type-i-interferonopathies\/. Accessed 14 Nov 2023."},{"issue":"4","key":"1826_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/jir.2017.0127","volume":"38","author":"H Kim","year":"2018","unstructured":"Kim H, de Jesus AA, Brooks SR, et al. Development of a validated interferon score using nanostring technology. J Interf Cytokine Res. 2018;38(4):171\u201385.","journal-title":"J Interf Cytokine Res"},{"issue":"4","key":"1826_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1172\/JCI129301","volume":"130","author":"AA de Jesus","year":"2019","unstructured":"de Jesus AA, Hou Y, Brooks S, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest. 2019;130(4):1669\u201382.","journal-title":"J Clin Invest"},{"issue":"3","key":"1826_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.33368","volume":"64","author":"Y Liu","year":"2012","unstructured":"Liu Y, Ramot Y, Torrelo A, et al. Mutations in proteasome subunit \u03b2 type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. 2012;64(3):895\u2013907.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1826_CR15","first-page":"1","volume":"33","author":"AA de Jesus","year":"2014","unstructured":"de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol. 2014;33(1):1\u201352.","journal-title":"Annu Rev Immunol"},{"key":"1826_CR16","doi-asserted-by":"crossref","unstructured":"Abers MS, Delmonte OM, Ricotta EE, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. Jci Insight. 2020;6(1):e144455.","DOI":"10.1172\/jci.insight.144455"},{"issue":"3","key":"1826_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2019","unstructured":"Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. New Engl J Med. 2019;382(3):211\u201321.","journal-title":"New Engl J Med"},{"issue":"4","key":"1826_CR18","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208\u201319.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"1826_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-000910","volume":"10","author":"D Jayne","year":"2023","unstructured":"Jayne D, Rovin B, Mysler E, et al. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus Sci Med. 2023;10(2): e000910.","journal-title":"Lupus Sci Med"},{"issue":"1","key":"1826_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000286","volume":"5","author":"KA Casey","year":"2018","unstructured":"Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1): e000286.","journal-title":"Lupus Sci Med"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01826-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-024-01826-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01826-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:46:32Z","timestamp":1777304792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-024-01826-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1007\/s10875-024-01826-2","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.B, T.L and J.M are cofounders of Cytodelics AB (Stockholm, Sweden) which produce and distribute whole blood cell stabilizer solutions used to preserve samples for cytometry analyses within this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"31"}}